t
Nuformix plc announced on 12 April 2022 the application for admission to trading of the second tranche of shares from a subscription with Lanstead Capital Investors L.P. This tranche comprises 88,000,000 Ordinary Shares for gross proceeds of £1,320,000, and 5,700,000 Second Value Payment Shares. Admission to trading is expected on 14 April 2022, following which the Company's enlarged issued share capital will consist of 709,309,368 Ordinary Shares.
| Date | 12 Apr 2022 |
| Time | 07:00:03 |
| Category | Capital structure |
| ID | 0005I |
12 April 2022
Nuformix plc
("Nuformix" or the "Company")
Second tranche of Lanstead subscription shares
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that further to the notifications of 14 December 2021 and 17 January 2022 relating to its subscription and associated sharing arrangements with Lanstead Capital Investors L.P. ("Lanstead"), application has now been made for trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission") for the second tranche of the subscription, comprising 88,000,000 Ordinary Shares (the "Second Subscription Shares") for gross proceeds of £1,320,000 and the associated 5,700,000 Second Value Payment Shares.
Full details of the subscription and associated sharing agreements and the Second Value Payment Shares are set out in the earlier announcements referenced above.
Admission and dealings in the Second Subscription Shares and the Second Value Payment Shares, all of which will rank pari passu with the existing Ordinary Shares, are expected to commence at 8.00 am on 14 April 2022.
Total Voting Rights
Following Admission of the Second Subscription Shares and the Second Value Payment Shares the Company's enlarged issued share capital will comprise 709,309,368 Ordinary Shares with voting rights. The figure of 709,309,368 Ordinary Shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
|
Nuformix plc |
|
|
Dr Alastair Riddell, Executive Chairman
|
Via IFC Advisory |
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
John Howes (Corporate Broking) |
+44 (0) 20 3650 3652
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.